Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Antiplatelet Therapy in ACS and A-Fib

Editor(s): Serebruany V.L. (Towson, Md.) 
Atar D. (Oslo) 

Status: available   
Publication year: 2012
Buy this book
Digital Version: CHF 142.00, EUR 133.00, USD 167.00
Print Version: CHF 142.00, EUR 133.00, USD 167.00
The final prices may differ from the prices shown due to specifics of VAT rules, postage and handling.
Order this title

You already have online access to this title. If you would like to buy a personal digital or print copy, please click here.

This book belongs to
Advances in Cardiology , Vol. 47
Editor(s): Borer J.S. (New York, N.Y.) 
VI + 170 p., 20 fig., 6 in color, 16 tab., hard cover, 2012
Status: available   
ISSN: 0065-2326
e-ISSN: 1662-2839

Written by top experts in the field
Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Anticoagulant and antiplatelet therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes.
With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers.
The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.